Rules Navigator

Register

Tackling fraud in Big Pharma: Realistic ambition or pipe dream?

A crowd has gathered around a bottle of fake medicine in this advertising trade card printed in New York City around 1880.
A New York trade card warning of fake medicine, from the 1880s. Photo: Transcendental Graphics/Getty Images

Trevor Francis | Blackfords

 Click to share on Facebook (Opens in new window/tab) Click to share on Twitter (Opens in new window/tab) Click to share on LinkedIn (Opens in new window/tab) Click to share on WhatsApp (Opens in new window/tab)

Any suggestion of misleading clinical results, false advertising, or bribery to achieve medical approvals would clearly create massive negative publicity.

Big Pharma, and the life sciences sector more generally, has always been susceptible to corruption. In fact, Transparency International, the NGO working to end the injustices of corruption and promote transparency, accountability and integrity, published a report in 2016 identifying pharmaceuticals as standing out as a sub-sector that was particularly

With

Free Trial

Register for free to keep reading.

To continue reading this article and unlock full access to GRIP, register now. You’ll enjoy free access to all content until our subscription service launches in early 2026.

  • Unlimited access to industry insights
  • Stay on top of key rules and regulatory changes with our Rules Navigator
  • Ad-free experience with no distractions
  • Regular podcasts from trusted external experts
  • Fresh compliance and regulatory content every day
Register for free Already a member? Sign in
, , , , , , , ,
You may also like